Stevens Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Stevens Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-10,679	Closed	-$159K	–	981
2015 Q2	$159K	Buy	+10,679	New	+$121K	0.01%	909
2014 Q4	–	Sell	-25,754	Closed	-$252K	–	1002
2014 Q3	$252K	Buy	+25,754	New	+$316K	0.01%	790

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Stevens Capital Management's BCRX Position: Q3 2015 in Review

Stevens Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2015, closing a stake of 10,679 shares — an estimated $159K sold.

Stevens Capital Management first reported a position in BCRX in Q3 2014 and held it in 2 quarters. The position peaked at $252K in Q3 2014. 124 funds tracked by Wall St. Rank hold BCRX as of Q3 2015.

Stevens Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Stevens Capital Management sold 10,679 BioCryst Pharmaceuticals shares in Q3 2015, an estimated $159K.
Stevens Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2014 and held it in 2 quarters.
Stevens Capital Management's BioCryst Pharmaceuticals position peaked at $252K in Q3 2014.
124 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2015.

Based on Stevens Capital Management's 13F filing for Q3 2015, filed 10 Nov 2015.